Victoria Smith

Victoria Smith

Company: Amphivena Therapeutics

Job title: Chief Scientific Officer

Seminars:

Chair Led Q&A 11:50 am

Read more

day: Track B - Day 1 AM

ReSTORE T Cell Engagers: Maintaining Immune Activation and Controlling CRS via Depletion of MDSC 11:00 am

AMV564, a bivalent T cell engager that targets MDSC, has shown monotherapy activity in solid tumor patients with limited evidence CRS Consistent with these clinical findings, the cytokine profile in patients treated with AMV564 shows strong induction of IFNγ and cytokines and chemokines driving T cell trafficking and activation, with limited IL6 ReSTORE pipeline molecules…Read more

day: Track B - Day 1 AM

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.